Paper

Mild-to-Moderate Active Luminal Crohn's Disease
Pierre Michetti^a, Pascal Juillerat^a, Christian Mottet^a, Valérie Pittet^c, Jean-Jacques Gonvers^a, John-Paul Vader^c, Florian Froehlich^{a, b}, Christian Felley<sup>a

a</sup>Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne,
^bGastrointestinal Department, University of Basle, Basle, and
^cHealthcare Evaluation Unit, Institute of Social and Preventive Medicine, University of Lausanne, Lausanne, Switzerland

Address of Corresponding Author

Digestion 2007;76:92-98 (DOI: 10.1159/000111022)

  Key Words

• Crohn's disease, review
• Crohn's disease, therapy
• Aminosalicylates
• Steroids
• Azathioprine

  Abstract

The management of luminal Crohn's disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease. Mild-to-moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients inversely correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies has not been thoroughly evaluated in patients with mild disease.

Copyright © 2008 S. Karger AG, Basel

  Author Contacts

Pierre Michetti, MD
Division of Gastroenterology and Hepatology
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46
CH-1011 Lausanne (Switzerland)
Tel. +41 21 314 06 90, Fax +41 21 314 07 07, E-Mail pierre.michetti@chuv.ch

  Article Information

Published online: February 7, 2008
Number of Print Pages : 7
Number of Figures : 0, Number of Tables : 0, Number of References : 50